Doug brings over two decades of experience in finance, investor relations, strategy and capital formation in the biopharmaceutical industry to Jnana. Doug has had finance and operational leadership roles in both public and venture-backed companies going through transitions from pre-clinical to clinical to commercialization. Prior to joining Jnana, he most recently served as the Chief Financial Officer of Dicerna Pharmaceuticals, where he oversaw the IT and Finance organizations and oversaw the sale of the company to Novo Nordisk for $3.3BN. Doug also served as Chief Financial Officer at KSQ Therapeutics and Paratek Pharmaceuticals, as well as Vice President of Finance at Acceleron Pharma, shepherding their IPO. Additionally, he served on the Board of Directors at Ziopharm Oncology, and held roles of increasing responsibility at Biogen, Bristol-Myers Squibb, Johnson & Johnson and JPMorgan earlier in his career. Doug earned his MBA in Finance & Accounting from Columbia Business School and a B.S.E. in Chemical Engineering with a concentration in Engineering Biology from Princeton University.